Overview
The recent authorization by Anvisa (Brazil’s Health Regulatory Agency) for the national production of the Active Pharmaceutical Ingredient (API) of infliximab by Bionovis marks a strategic step for the health and national security of Brazil. The biopharmaceutical, essential for treating autoimmune diseases, symbolizes the effort to reverse the critical dependence on imported inputs, which currently accounts for about 95% of the total. This article explores the historical importance of this recovery, the structural and professional capacity challenges involved, and the crucial role of policies such as the Productive Development Partnerships (PDPs) for the rebirth of the Health Economic-Industrial Complex (CEIS).
Introduction
The Pandemic’s Wake-Up Call and the Historic Decline
Brazil faces a paradox in healthcare: a robust Unified Health System (SUS) coexisting with an extreme vulnerability in drug production. Currently, only 5% of Active Pharmaceutical Ingredients (APIs)—the essential raw material for medicines—are produced on national territory. This figure was as high as 50% a few decades ago.
The COVID-19 crisis dramatically exposed this fragility: the interruption of global supply chains, primarily concentrated in China and India, led to drug shortages and price hikes, jeopardizing public health and national security. Sanitary sovereignty, which seemed a distant concept, became a strategic urgency.
From the Infliximab API to the Challenges of Recovery
The Turning Point: National Infliximab
Anvisa’s approval for the production of the infliximab API (used to treat conditions like rheumatoid arthritis and Crohn’s disease) by Bionovis, a national pharmaceutical joint venture, is the first major sign that the country is determined to change this scenario. This initiative, resulting from Productive Development Partnerships (PDPs), is not just a technological achievement; it is a political-industrial milestone that strengthens the Health Economic-Industrial Complex.
The Obstacles in the Race for Autonomy
Despite the excitement, the path to sanitary sovereignty is full of challenges. Experts like Azi Mauricio (ICTQ Professor) and João Paulo Sartin Mendes (Pharmacist) are emphatic: API production is a matter of public health, economy, and security.
Industrial Obsolescence: The landscape includes about 37 national manufacturers, but most still operate with predominantly manual processes, limiting scale and competitiveness.
Workforce Shortage: There is a notable scarcity of specialized labor in high-complexity areas such as biotechnology and pharmachemistry.
Unequal Competition: National industries face unfair competition with countries that offer massive tax incentives and significantly lower production costs.
Accelerating PDPs and Investment in Innovation
The recovery demands a coordinated effort on several fronts:
Structural Investment: Focus on innovation, cutting-edge technology, and the automation of manufacturing processes.
Public Policies: Implementation of continuous and strategic policies that incentivize the national pharmachemical industry, such as the New Brazil Industry (NIB) program.
Agility in PDPs: Productive Development Partnerships (PDPs), like the infliximab project, are the ideal tool for technology transfer and stimulating local production. However, they need to gain more agility and effective monitoring to deliver timely results.
Conclusion
The Future of Health Depends on Qualification
The local production of the infliximab API is more than just a medicine: it is proof that the rebuilding of the Health Economic-Industrial Complex (CEIS) is viable and urgent. The goal is to reduce Brazil’s vulnerability to global crises and ensure uninterrupted access to essential treatments within the SUS.
To sustain this transformation, the sector will need, more than ever, qualified professionals. This is where qualification becomes the key. Institutions like ICTQ recognize this strategic demand and offer specializations designed to train the new leadership for the sector. Courses such as Regulatory Affairs, Quality Management and Auditing in the Pharmaceutical Industry, Analytical R&D and Quality Control in the Pharmaceutical Industry, and Pharmaceutical Industrial Management and Technology are crucial for empowering the leaders who will drive innovation, automation, and the competitiveness of national API production, effectively ensuring the country’s sanitary sovereignty.
GRP Brazil
If you are interested in registering your products in Brazil, GRP is ready to help. Our team of experts can simplify the process of registering products in Brazil and make it easier to schedule meetings with Anvisa more efficiently.
GRP can act as your local Agent & Register your product in U.S
Contact our team today to Inquire!
Email: info@globalregulatorypartners.com
Telephone : (+1) 781-672-4200
References
Learn more about Anvisa.
About Global Regulatory Partners
Global Regulatory Partners Inc, (GRP) is an American company that provides regulatory affairs, clinical, quality and safety services to medical devices, pharmaceutical, cosmetic and Food Supplement companies globally.
GRP headquarters is located in Massachusetts USA and its main affiliates are located in China, Japan, Brazil, Mexico and South Korea. GRP helps many life science companies register their products in different countries in compliance with local regulations.